Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
2021;4(1):e2033448
Third-Party Tested: Independent HPLC and mass spectrometry on every single batch not self-certified
Quick Comparison: Eloralintide vs Retatrutide Attribute Eloralintide Retatrutide Developer Eli Lilly Eli Lilly Class Selective amylin receptor agonist (LY-3841136 class) Triple agonist (LY3437943) Receptors targeted Amylin receptor only GIP + GLP-1 + glucagon Administration in trials Once weekly Once weekly, subcutaneous Phase 2 population 263 adults with obesity or overweight plus at least one obesity-related comorbidity, without type 2 diabetes 338 participants with obesity or overweight with weight-related conditions, excluding type 2 diabetes Phase 2 duration 48 weeks 48 weeks Reported mean weight reduction 9.5%-20.1% across arms vs 0.4% placebo (~20.1% at 9 mg) Up to 24.2% (~26.2 kg / ~58 lb) at the highest dose Tolerability signal Mild-to-moderate GI events
Esther Formula
Over time, scientists began noticing another fascinating benefit: GHK-Cu also stimulates hair regrowth
A case of delayed onset pyroglutamic acidosis in the sub-acute setting
US$ 24.21
US$ 21.23
US$ 21.89
US$ 21.51
US$ 24.80
